Recommendations from the EGAPP Working Group: Does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?

Genetics in Medicine

Volumn 18, Issue 8, 2016, Pages 770-779

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DISTANT METASTASIS; GENE EXPRESSION PROFILING; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; LYMPH NODE METASTASIS; MEDICAL SOCIETY; MULTICENTER STUDY (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TUMOR GENE; UNITED STATES; VALIDITY; BREAST NEOPLASMS; FEMALE; GENETICS; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PROCEDURES;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; PRECISION MEDICINE;

EID: 84981294759     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2015.173     Document Type: Article

References (54)

1. EGAPP Working Group. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med 2009; 11: 66-73
2. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Version 3.2013. http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf. Accessed 9 December 2015
3. Hassett MJ, Silver SM, Hughes ME, et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol 2012; 30: 2218-2226
4. American Cancer Society. Breast Cancer Facts and Figures 2015. http://www. cancer.org/research/cancerfactsstatistics/breast-cancer-facts-figures. Accessed 9 December 2015
5. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level metaanalysis of randomised trials. Lancet 2011; 378: 771-784
6. Davies C, Pan H, Godwin J, et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-Term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-816
7. Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-Analyses of longterm outcome among 100, 000 women in 123 randomised trials. Lancet 2012; 379: 432-444
8. Adjuvant! Online. http://www.adjuvantonline.com
9. Goldhirsch A, Winer EP, Coates AS, et al. Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-2223
10. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992; 22: 207-219
11. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ; Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747
12. Coates AS, Colleoni M, Goldhirsch A. Is adjuvant chemotherapy useful for women with luminal a breast cancer? J Clin Oncol 2012; 30: 1260-1263
13. Hayes DF Targeting adjuvant chemotherapy: a good idea that needs to be proven! J Clin Oncol 2012 30 1264-1267
14. Marchionni L, Wilson RF, Marinopoulos SS, et al. Impact of gene expression profiling tests on breast cancer outcomes. Evid Rep Technol Assess 2007; 160: 1-105
15. Ishibe N, Schully S, Freedman A, Ramsey SD. Use of Oncotype DX in Women with Node-Positive Breast Cancer. PLoS currents. 2011; 3: RRN1249
16. Smartt P. A comparison of gene expression profiling tests for breast cancer. HSAC Report 2010; 3
17. Medical Advisory Secretariat. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. Ont Health Technol Assess Ser 2010; 10: 1-57
18. Ward S, Scope A, Rafia R, et al. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis. Health Technol Assess (Winchester, England) 2013; 17: 1-302
19. Hornberger J, Alvarado MD, Rebecca C, Gutierrez HR, Yu TM, Gradishar WJ. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. J Natl Cancer Inst 2012; 104: 1068-1079
20. Rouzier R, Pronzato P, Chereau E, Carlson J, Hunt B, Valentine WJ. Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Res Treat 2013; 139: 621-637
21. Marrone M, Stewart A, Dotson WD. Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews. Genet Med 2015; 17: 519-532
22. Genomic Health. Oncotype DX Breast Cancer Assay http//www. genomichealth.com/sitecore/content/ODX-Breast/Home.aspx'sc-lang=en-US. Accessed 14 July 2015
23. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-Treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826
24. Teutsch SM, Bradley LA, Palomaki GE, et al. EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009; 11: 3-14
25. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734
26. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010; 28: 1829-1834
27. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006; 8: R25
28. Albain KS, Barlow WE, Shak S, et al. Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11: 55-65
29. Sestak I, Dowsett M, Zabaglo L, et al. Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 2013; 105: 1504-1511
30. Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013; 14: 1067-1076
31. Tang G, Shak S, Paik S, et al. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2011; 127: 133-142
32. Tang G, Cuzick J, Costantino JP, et al. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol 2011; 29: 4365-4372
33. Meleth S, Reeder-Hayes K, Ashok M, et al. Technology assessment of molecular pathology testing for the estimation of prognosis for common cancers. AHRQ Technology Assessment Report Project ID CANG0212. Agency for Healthcare Research and Quality: Rockville, MD, 2014. http://www.cms.gov/Medicare/Coverage/DeterminationProcess/Downloads/id94TA.pdf. Accessed 9 December 2015
34. Chen C, Dhanda R, Tseng WY, Forsyth M, Patt DA. Evaluating use characteristics for the Oncotype DX 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer. J Oncol Pract 2013; 9: 182-187
35. ClinicalTrials.gov. Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (the TAILORx Trial) NCT00310180. http://clinicaltrials. gov/show/NCT00310180
36. Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006; 7: 347-350
37. Lo SS, Mumby PB, Norton J, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010; 28: 1671-1676
38. Holt S, Bertelli G, Humphreys I, et al. A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K. Br J Cancer 2013; 108: 2250-2258
39. Eiermann W, Rezai M, Kummel S, et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-Adapted change in chemotherapy use. Ann Oncol 2013; 24: 618-624
40. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-1452
41. ClinicalTrials.gov. Tamoifen Citrate, Letrozole, Anastrozole, or Exemestane, With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer. NCT01272037. http://clinicaltrials.gov/show/NCT01272037. Accessed 9 December 2015
42. Brewer NT, Richman AR, DeFrank JT, Reyna VF, Carey LA. Improving communication of breast cancer recurrence risk. Breast Cancer Res Treat 2012; 133: 553-561
43. Tzeng JP, Mayer D, Richman AR, et al. Women's experiences with genomic testing for breast cancer recurrence risk. Cancer 2010; 116: 1992-2000
44. Spellman E, Sulayman N, Eggly S, et al. Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives. Psychooncology 2013; 22: 2110-2116
45. Sulayman N, Spellman E, Graves KD, et al. Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS. J Cancer Epidemiol 2012; 2012: 728290
46. Bombard Y, Rozmovits L, Trudeau ME, Leighl NB, Deal K, Marshall DA. Patients? perceptions of gene expression profiling in breast cancer treatment decisions. Curr Oncol 2014; 21: e203-e211
47. Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013; 31: 2783-2790
48. Lamond NW, Skedgel C, Younis T. Is the 21-gene recurrence score a costeffective assay in endocrine-sensitive node-negative breast cancer? Expert Rev Pharmacoecon Outcomes Res 2013; 13: 243-250
49. UK National Institute for Health and Care Excellence Diagnostics Guidance. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat. September 2013. http://publications. nice.org.uk/gene-expression-profiling-And-expanded-immunohistochemistrytests-for-guiding-Adjuvant-chemotherapy-dg10. Accessed 9 December 2015
50. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312
51. Senkus E, Kyriakides S, Penault-Llorca F, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(suppl 6): vi7-23
52. Azim HA, Jr, Michiels S, Zagouri F, et al. Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol 2013; 24: 647-654
53. BlueCrossBlueShield Association TEC Assessment. Gene expression profiling in women with lymph node-negative breast cancer to select adjuvant chemotherapy. October 2014. http://www.bcbs.com/blueresources/tec/vols/29/29-3.html
54. Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015; 373: 2005-2014